Until his retirement, Dr. Roscoe M. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for global development support within the Office of the Secretary, HHS, with primary emphasis on Continental Africa and other less developed countries of the world (e.g., Indonesia, Malaysia, and Vietnam). He was the principal liaison person between the HHS and Ministries of Health in Africa with regard to the development of infrastructure and technical support for the delivery of preventive and curative health needs for the continent. Dr. Moore represented the HHS in cooperative international efforts with African nations in addressing continued health and human resources issues.
Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop.
Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (CDC). He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. Dr. Moore has been acknowledged as the "Father" of Medical Device Epidemiology by FDA for establishing the first Medical Device Epidemiology Training Fellowship Program within the USPHS. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.
Dr. Moore has international experience with countries of North Africa (Morocco), North West Africa (Mauritania), Sub-Saharan Africa, West Africa (Senegal, Nigeria, and Mali), Central Africa (Central African Republic, Republic of Congo, Rwanda, and Uganda), East Africa (Kenya, Mozambique, and Tanzania) and Southern Africa (South Africa and the countries of the Southern African Development Community [SADC]). He also has experience in England, Israel, Switzerland, Norway, Ireland, Spain, France, Italy, Germany, Austria, the former Yugoslavia (Serbia, Macedonia, and Croatia), Poland, Mexico, Canada, Indonesia, Malaysia, Vietnam, China, and Caribbean Nations (Bahamas, Barbados, Dominican Republic, Haiti, Jamaica, and Puerto Rico). During his career and while on official duty, Dr. Moore has traveled to 44 of the 50 states in the United States of America.
Dr. Moore has conducted clinical research on infectious diseases such as Venezuelan equine encephalitis, tuberculosis, listeriosis, psittacosis, human Orf, malaria, and HIV/AIDS. He has carried out epidemiological research on a number of chronic and molecular diseases; for example, lead toxicosis, occupational and environmental cancers, and sickle cell disease. Dr. Moore has evaluated the safety and effectiveness of medical devices, and conducted relevant epidemiological research on the utilization experience and human health effects of medical devices and radiation. He was involved in the development of a sustainable infrastructure for the surveillance of emerging and re-emerging diseases worldwide. He continues to be involved in issues of terrorism (and bio-terrorism), the evaluation of vaccines, the safety of bio-engineered foods, food security, Avian Influenza (H5N1, H1N1), safe blood transfusions, blood substitutes, prevention and treatment for eye diseases (glaucoma), diabetes, allergens (Japanese red cedar, Latex), intestinal parasites (tapeworms), telehealth/telemedicine, adult stem cell research (Parkinson's disease), autism and Alzheimer's research, placental hormones (human placental lactogen), therapeutic nutritional supplementation and probiotics, oral rehydration therapy, pain therapy, and disaster response and crisis mitigation.
Dr. Moore has written or co-authored over 100 publications covering a broad range of public health issues. He is a Fellow of the American College of Epidemiology. Dr. Moore serves on the Board of Trustees for Friends of the University of Stellenbosch Foundation. He is a life-member of Delta Omega, the honorary society in public health at the Johns Hopkins University. Dr. Moore and his wife have established a scholarship in their names for Ph.D. candidates in Epidemiology at the Johns Hopkins University.
Dr. Moore served on the Fogarty International Center Advisory Board of Directors, NIH, appointed by the U.S. Secretary of Health and Human Services. Dr. Moore served as an Adjunct Professor of Epidemiology, Medical University of Southern Africa, Pretoria, South Africa. He served on the Alumni Board of Directors, School of Public Health, University of Michigan. Dr. Moore served on the Dean's Alumni Council, Bloomberg School of Public Health, Johns Hopkins University. He served as an Affiliate Associate Professor of Environmental Health for the University of Washington, Seattle. He served on the Board of Directors for the Africa Center for Health and Human Security, George Washington University. Dr. Moore served as an Adjunct Professor of Epidemiology, University of Hanoi, Vietnam. He served as a Visiting Professor, International Postgraduate School, European Center for Peace and Development, United Nations University for Peace. Dr. Moore served as Counterpart Investigator within the Clinic of Gynecology and Obstetrics, Faculty of Medicine, University of Belgrade, Serbia.
Dr. Moore holds a First Degree Black Belt in karate and is very active in the community. He served on the Board of Directors and the Executive Committee for what is now the MedStar Montgomery Medical Center in Olney, Maryland. Dr. Moore served on the Board of Directors and as President for the Friends of the National Zoo (FONZ) in Washington, DC. Dr. Moore served as a Commissioner for the Maryland Health Care Commission, appointed by the Governor. He has been designated by the Governor of the Commonwealth of Virginia as a Virginia Hero. Dr. Moore served as Chair of the Washington Suburban Sanitary Commission which has a $1.5 billion dollar annual budget.
Dr. Moore is the Founder and President of PH RockWood Corporation which is focused on the prevention, treatment and control of infectious diseases worldwide. He is a Senior Fellow of the Potomac Institute for Policy Studies. Dr. Moore is Chair of the Board of Advisors for Immunomic Therapeutics Incorporated, a DNA vaccine company. He serves on the Scientific Advisory Board of Cera Products Incorporated which produces rice-based oral rehydration therapies. Dr. Moore serves on the Scientific Advisory Board of HemoBioTech Incorporated, a publicly traded company developing a novel safe substitute for human blood. He serves on the Scientific Advisory Board for Telcare LLC which is focused on the clinical management of diabetes. Dr. Moore serves on the Scientific Advisory Board of ImQuest Life Sciences which is focused on early stage anti-infective and anti-cancer drugs, and vaccine development services. He serves as Chief Scientific Director for MusclePharm Corporation, a publicly traded therapeutic nutritional supplement company. He serves on the Scientific Advisory Board of VectraCor Incorporated, which has a patent for monitoring and detecting a "heart attack". Dr. Moore serves as Chairman of the Board of Directors of ImmunoClin; a London based Biotechnology Company with therapeutic candidates for HIV and other infectious diseases, and diagnostics for cardiovascular disease and Alzheimer's disease risk. Dr. Moore serves on the Board of Directors for Biodefense Gamma LLC which specializes in purified gamma globulin therapy for a number of infectious diseases. He serves on the Scientific Advisory Board for Cannabis Science Incorporated, a publicly traded company which is at the forefront of phytocannabinoid-based treatments for HIV and certain skin cancers.
Dr. Moore serves on the Board of Directors for the Safe Blood for China Foundation. He serves on the Board of Directors for the Greater Silver Spring (Maryland) Chamber of Commerce. Dr. Moore serves on the Board of Directors for Constituency for Africa. He is a Senior Advisor to PeerSat Corporation.
Harold Smith is a tenured professor of biochemistry and biophysics at the University of Rochester, School of Medicine and Dentistry. Dr. Smith's primary function at the University is basic research and in this context he is fully engaged in biomedical laboratory research as well as training postdocs, graduate and undergraduate students.
The Smith lab's primary interest is understanding the composition, regulation and structure of macromolecular complexes involved in regulating gene expression at the level of messenger RNA expression and processing. Our focus is on a platform of enzymes that change the genetic code at the DNA or RNA level by deaminating cytidine to form uridine. Current data suggest that this family of cytidine deaminase function with other proteins (auxiliary proteins) as holoenzymes complexes which we refer to as editosomes (for RNA) or mutasomes (for DNA). RNA editing or DNA mutational activity by these enzymes affect the protein coding capacity of mRNAs and thereby can diversify the proteins that are expressed by cells (the proteome).
The lab is harnessing the power of molecular engineering, genomics, protein biochemistry and cell biology to address how the activity and specificity of these enzymes are controlled by cells such that only select nucleic acids are affected, at the appropriate time and only in appropriate cells. Proper regulation of enzyme expression and activity is important for normal biological responses such as anti-viral host cell defense, dietary lipid transport in the blood and enabling a specific and robust immune response. Conversely, when these enzymes are not expressed or their activity is blocked or inappropriately activated, diseases may be acquired such as AIDS, atherosclerosis, cancer and immunodeficiency.
David Miller MSW, MPH, PhD is the Protocol Chair of University of Rochester Center for AIDS Research Community Advisory Board. David is a former Board Member of the AIDS Institute, the Treatment/Policy Education Advocacy Coordinator at the National Association of People with AIDS and the former Chair of the NYC HIV Planning Council PLWA Advisory Group, the Bronx HIV CARE Network and The Global Network of People w. AIDS (GNP+). David is a contributing reporter to HIV Plus Magazine, A&U Magazine and PanAware. He's published dozens of articles over the past 30 years, reporting on proceedings at international scientific conferences.
David is a member of the International AIDS Society and The International Association of Providers in AIDS Care and has been involved in multiple campaigns with The AIDS Treatment Activist Coalition and the Campaign to End AIDS.
David was an active member of ACT UP NY from 1987 until 2002 and a regular participant in AIDSWatch, the largest national legislative advocacy effort focused on federal funding for HIV/AIDS treatment, research and cure.
A Native New Yorker, David now lives in Rochester, NY. He serves as Director of the Advisory Board for OyaGen Inc., a biotechnology firm developing novel therapeutics for infectious diseases. David is an honorably discharged, decorated veteran of the 69th Inf. 42nd Div. NY Army Reserve Nat'l Guard and was involved in the immediate rescue efforts at Ground Zero during the 9/11 attacks. He attended St. John's University, Dartmouth and Tufts University. He also provides insights in popular molecular epidemiology for Advanced BioStrategies, Inc., a life science consulting firm.
"Germinator Genesis platform and the SHIELD microbial barrier application are at the forefront for facilities' remediation of infectious diseases. This allows for patients, providers, consumers and commuters to have a high degree of confidence in the facility's safety. This is an absolute necessity during the current Covid19 pandemic." -David Miller
Chad S. Johnson, Esq., is a Harvard-trained corporate, legislative, and regulatory attorney with significant experience in advising health and biotechnology companies, both public and private, and pursuing entrepreneurial ventures. After clerking for a federal judge, Chad joined top law firm Skadden, Arps, Slate, Meagher & Flom LLP in its Washington, DC office where he focused on financial institution regulatory law, political law, and substantial pro bono advocacy on behalf of civil rights and civic organizations. Leaving the firm after several years to work on a presidential campaign as deputy national director of business leader outreach. Chad continues to pursue interests in national politics and has worked as a business leader, board member, and legal counsel for domestic and international health-related, drug-development, and biotechnology companies and non-profit organizations, with a focus on entrepreneurial ventures in biotechnology and pathogen-related treatment and mitigation. A newer interest includes a start-up in international sports team fan engagement. Chad remains active in the Harvard College and Harvard Law School alumni associations, volunteering to interview DC-area candidates for admission to Harvard College. Originally from Emporia, Kansas, Chad has lived and worked in Washington, DC and/or the DC metro area since 1993, particularly enjoying a home in a rural area on the Shenandoah River near Harpers Ferry, West Virginia.
Read More Read LessDr. Noller has been a pioneer in the agricultural field, providing 21 years of leadership at Oregon State University (OSU). He is currently the director and lead researcher at OSU's Global Hemp Innovation Center, the largest US-based hemp research center. The center's mission is to advance the research of hemp and its market potential across multiple, diverse industries and research fields to serve the growing international demand for innovative approaches to food, health, and fiber.
"I am looking forward to working alongside Germinator as a member of its esteemed Scientific Board in a continued effort to research and understand the transmission of emerging pathogens onto food and surfaces, There is still so much work to be done when it comes to understanding the way germs, bacteria and viruses interact with different environments, and this knowledge is key to developing innovative measures to remedy the risk of exposure and spread."
